The 2025 list of medical technologies approved for innovation funding (NUB) released in Germany

On January 30, 2025, the Institute for the Hospital Remuneration System (InEK) published the list of requests for innovation funding (NUB) submitted by hospitals in 2024. The medical technologies of cardiovascular, endoscopy, extracorporeal, gastrointestinal, neuromodulation, peripheral vascular, and other technology groups obtained positive status 1.

Out of 1,025 submitted technologies, 300 (29%) received positive status 1, which means that the suggested procedure or medical device met the NUB criteria. Now, hospitals can negotiate innovation funding for these technologies with sickness funds. 

Furthermore, 13 (1%) of technologies received differentiated status, which means that status 1 is granted only under certain conditions.

Below are some examples of medical technologies that obtained status 1. The technologies with differentiated status were not included in the list.

• Ascites treatment using a fully implantable pump;
• Endoscopic performance of sleeve gastrectomy (endoscopic sleeve gastroplasty);
• Endoscopic suture system for continuous single sutures and continuous sutures for bariatric surgery;
• Endovascular implantation of an extracorporeal centrifugal pump for circulatory support;
• Endovascular implantation of a tricuspid valve replacement;
• Endovascular mitral valve annuloplasty with annuloplasty band;
• Joint transplants with thin-layer, fresh, living, allogeneic cartilage or bone material;
• Implantation of a gastric pacemaker;
• Insertion of coated (covered) stents with the bioactive surface for intra-abdominal, cranial, or peripheral vessels;
• Personalized external aortic root support (PEARS);
• Replacement of a heart valve or a prosthetic heart valve with a decellularized allograft;
• Thrombectomy of pulmonary vessels using the disc retriever system;
• Treatment of scoliosis using magnetically controlled rods;
• Uterus transplantation;
• Wireless cardiac stimulation system of the left ventricle for cardiac resynchronization therapy.

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.